{"component": "contracts", "props": {"contracts": [{"intro": "AWARD/CONTRACT 1. THIS CONTRACT IS A RATED ORDER UNDER DPAS (15 CFR 700) \u00d8 RATING PAGE OF PAGES 1 63 2. CONTRACT (Proc. Inst. Ident.) NO.HHSO100201700014C 3. EFFECTIVE DATESee Block 20C 4. REQUISITION/PURCHASE REQUEST/PROJECT NO.OS202400 6. ISSUED BY CODE ASPR-BARDA 6. ADMINISTERED BY (If other than Item 5) CODE ASPR-BARDA02 \nASPR-BARDAO\u2019NEILL HOUSE OFFICE BUILDINGWashington DC 20515\n\n \nUS DEPT OF HEALTH & HUMAN SERVICESASST SEC OF PREPAREDNESS & RESPONSEACQ MANAGEMENT, CONTRACTS, & GRANTSO\u2019NEILL HOUSE OFFICE BUILDINGWashington DC 20515 7. NAME AND ADDRESS OF CONTRACTOR (No., Street, City, County, State and ZIP Code)\nSUMMIT (OXFORD) LIMITED 1510803[**]; 85B PARK DRIVE85B PARK DRIVEMILTON PARKABINGDON OXFORDSHIRE OX14\n\n\n 8. DELIVERY \u00a8 FOB ORIGIN x OTHER (See below) 9. DISCOUNT FOR PROMPT PAYMENT\n\n\n\n 10. SUBMIT NOTICES(4 copies unless otherwise specified)TO THE ADDRESS SHOWN IN \u00d8\n ITEM CODE 1510803 FACILITY CODE 11. SHIP TO/MAKE FOR CODE HHS/OS/ASPR 12. PAYMENT WILL MADE BY CODE DHHS/FMS", "id": "6nuf37NlVgw", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000162828018004229/sum-ex426_20180131x20f.htm", "category_name": "Contract", "company_name": "Summit Therapeutics PLC", "created": "April 13th, 2018", "published": true, "pretty": null, "uri": "/contracts/6nuf37NlVgw", "title": "Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions.", "group_id": "6nuf37NlVgw", "group_samples": [{"label": "Contract (Summit Therapeutics PLC)", "uri": "/contracts/6nuf37NlVgw", "published": true}], "group_size": 1, "tags": [{"name": "Contract", "type": "category", "uri": "/contracts/tagged/contract"}, {"name": "Summit Therapeutics PLC", "type": "company", "uri": "/company/1599298/summit-therapeutics-plc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "", "id": "7Lu7eBblgnS", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000159929823000034/amd1tosublease.htm", "category_name": "Sublease", "company_name": "Summit Therapeutics Inc.", "created": "March 9th, 2023", "published": true, "pretty": null, "uri": "/contracts/7Lu7eBblgnS", "title": "Contract", "group_id": "7Lu7eBblgnS", "group_samples": [{"label": "Sublease (Summit Therapeutics Inc.)", "uri": "/contracts/7Lu7eBblgnS", "published": true}], "group_size": 1, "tags": [{"name": "Sublease", "type": "category", "uri": "/contracts/tagged/sublease"}, {"name": "Summit Therapeutics Inc.", "type": "company", "uri": "/company/1599298/summit-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "", "id": "7aeTvNGw9kY", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000119312516587491/d185299dex421.htm", "category_name": "Second Variation Agreement", "company_name": "Summit Therapeutics PLC", "created": "May 12th, 2016", "published": true, "pretty": null, "uri": "/contracts/7aeTvNGw9kY", "title": "DATED 16th November 2015 - and - - and - SECOND VARIATION AGREEMENT relating to the Agreement for the Sponsorship of a Research Programme for the development of small molecule modulators of utrophin for the treatment of Duchenne Muscular Dystrophy...", "group_id": "7aeTvNGw9kY", "group_samples": [{"label": "Second Variation Agreement (Summit Therapeutics PLC)", "uri": "/contracts/7aeTvNGw9kY", "published": true}], "group_size": 1, "tags": [{"name": "Second Variation Agreement", "type": "category", "uri": "/contracts/tagged/second-variation-agreement"}, {"name": "Summit Therapeutics PLC", "type": "company", "uri": "/company/1599298/summit-therapeutics-plc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "England and Wales", "type": "jurisdiction", "uri": "/contracts/tagged/england-and-wales-gb"}]}, {"intro": "BY SUMMIT CORPORATION PLC (registered number 05197494 whose registered office is at 85b Park Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RY (\u201cthe Company\u201d).", "id": "7nHBBI7oqd1", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000095012314012620/filename16.htm", "category_name": "Emi Option Agreement", "company_name": "Summit Corp PLC", "created": "December 4th, 2014", "published": true, "pretty": null, "uri": "/contracts/7nHBBI7oqd1", "title": "SUMMIT CORPORATION PLC EMI OPTION AGREEMENT \u00abForename\u00bb \u00abSurname\u00bb", "group_id": "7nHBBI7oqd1", "group_samples": [{"label": "Emi Option Agreement (Summit Corp PLC)", "uri": "/contracts/7nHBBI7oqd1", "published": true}], "group_size": 1, "tags": [{"name": "Emi Option Agreement", "type": "category", "uri": "/contracts/tagged/emi-option-agreement"}, {"name": "Summit Corp PLC", "type": "company", "uri": "/company/1599298/summit-corp-plc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This letter will confirm our discussion concerning the separation of your employment with Summit Therapeutics Inc. (the \u201cCompany\u201d) effective on July 2, 2021 (the \u201cSeparation Date\u201d).", "id": "7oqV4Ok99Dn", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000092189521001523/ex101to8k12566003_05282021.htm", "category_name": "Separation Agreement", "company_name": "Summit Therapeutics Inc.", "created": "May 28th, 2021", "published": true, "pretty": null, "uri": "/contracts/7oqV4Ok99Dn", "title": "May 28, 2021 Michael Donaldson Concord, MA 01742 Dear Michael:", "group_id": "7oqV4Ok99Dn", "group_samples": [{"label": "Separation Agreement (Summit Therapeutics Inc.)", "uri": "/contracts/7oqV4Ok99Dn", "published": true}], "group_size": 1, "tags": [{"name": "Separation Agreement", "type": "category", "uri": "/contracts/tagged/separation-agreement"}, {"name": "Summit Therapeutics Inc.", "type": "company", "uri": "/company/1599298/summit-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "This REGISTRATION RIGHTS AGREEMENT (this \u201cAgreement\u201d) is made and entered into as of January 9, 2019 by and among Summit Therapeutics plc, a public limited company incorporated in England and Wales with the Registrar of Companies of England and Wales (the \u201cCompany\u201d), and the \u201cInvestor\u201d named in that certain Securities Purchase Agreement by and among the Company and the Investor (the \u201cPurchase Agreement\u201d). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.", "id": "8NTbx29oL4y", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000119312519005734/d683406dex21.htm", "category_name": "Registration Rights Agreement", "company_name": "Summit Therapeutics PLC", "created": "January 10th, 2019", "published": true, "pretty": null, "uri": "/contracts/8NTbx29oL4y", "title": "REGISTRATION RIGHTS AGREEMENT", "group_id": "8NTbx29oL4y", "group_samples": [{"label": "Registration Rights Agreement (Summit Therapeutics PLC)", "uri": "/contracts/8NTbx29oL4y", "published": true}], "group_size": 1, "tags": [{"name": "Registration Rights Agreement", "type": "category", "uri": "/contracts/tagged/registration-rights-agreement"}, {"name": "Summit Therapeutics PLC", "type": "company", "uri": "/company/1599298/summit-therapeutics-plc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This SECURITIES PURCHASE AGREEMENT (this \u201cAgreement\u201d) is dated as of September 28, 2026, by and between Summit Therapeutics Inc., a Delaware corporation (the \u201cCompany\u201d), and AstraZeneca Holdings B.V., a Dutch private limited liability company (the \u201cInvestor\u201d).", "id": "9MKEVEz55f4", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000119312526405776/d178892dex101.htm", "category_name": "Securities Purchase Agreement", "company_name": "Summit Therapeutics Inc.", "created": "September 29th, 2026", "published": true, "pretty": null, "uri": "/contracts/9MKEVEz55f4", "title": "SECURITIES PURCHASE AGREEMENT", "group_id": "9MKEVEz55f4", "group_samples": [{"label": "Securities Purchase Agreement (Summit Therapeutics Inc.)", "uri": "/contracts/9MKEVEz55f4", "published": true}], "group_size": 1, "tags": [{"name": "Securities Purchase Agreement", "type": "category", "uri": "/contracts/tagged/securities-purchase-agreement"}, {"name": "Summit Therapeutics Inc.", "type": "company", "uri": "/company/1599298/summit-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "", "id": "9k6zIIYU3m", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000119312517104086/d365559dex423.htm", "category_name": "License and Collaboration Agreement", "company_name": "Summit Therapeutics PLC", "created": "March 30th, 2017", "published": true, "pretty": null, "uri": "/contracts/9k6zIIYU3m", "title": "LICENSE AND COLLABORATION AGREEMENT by and between SUMMIT (OXFORD) LTD and SAREPTA THERAPEUTICS, INC. Dated as of October 3, 2016", "group_id": "9k6zIIYU3m", "group_samples": [{"label": "License and Collaboration Agreement (Summit Therapeutics PLC)", "uri": "/contracts/9k6zIIYU3m", "published": true}], "group_size": 1, "tags": [{"name": "License and Collaboration Agreement", "type": "category", "uri": "/contracts/tagged/license-and-collaboration-agreement"}, {"name": "Summit Therapeutics PLC", "type": "company", "uri": "/company/1599298/summit-therapeutics-plc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "The ADSs will be evidenced by American Depositary Receipts (\u201cADRs\u201d) issued pursuant to that certain Deposit Agreement dated [ ], 2015 (the \u201cDeposit Agreement\u201d), by and among the Company, The Bank of New York Mellon, as depositary (the \u201cDepositary\u201d), and all holders and beneficial owners of ADSs issued thereunder. The Ordinary Shares to be issued in connection with, and represented by, the ADSs are hereinafter referred to as the \u201cUnderlying Securities.\u201d", "id": "MlwyfTXDLp", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000119312515056561/d822352dex11.htm", "category_name": "Underwriting Agreement", "company_name": "Summit Therapeutics PLC", "created": "February 20th, 2015", "published": true, "pretty": null, "uri": "/contracts/MlwyfTXDLp", "title": "] American Depositary Shares Representing [ ] Ordinary Shares (Par Value \u00a30.01 Per Share) SUMMIT THERAPEUTICS PLC UNDERWRITING AGREEMENT", "group_id": "MlwyfTXDLp", "group_samples": [{"label": "Underwriting Agreement (Summit Therapeutics PLC)", "uri": "/contracts/MlwyfTXDLp", "published": true}], "group_size": 1, "tags": [{"name": "Underwriting Agreement", "type": "category", "uri": "/contracts/tagged/underwriting-agreement"}, {"name": "Summit Therapeutics PLC", "type": "company", "uri": "/company/1599298/summit-therapeutics-plc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "", "id": "cByajbS28Zt", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000159929823000012/redactedakeso-summitcomm.htm", "category_name": "Common Stock Issuance Agreement", "company_name": "Summit Therapeutics Inc.", "created": "January 20th, 2023", "published": true, "pretty": null, "uri": "/contracts/cByajbS28Zt", "title": "EXECUTION Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omitted information. 1...", "group_id": "cByajbS28Zt", "group_samples": [{"label": "Common Stock Issuance Agreement (Summit Therapeutics Inc.)", "uri": "/contracts/cByajbS28Zt", "published": true}], "group_size": 1, "tags": [{"name": "Common Stock Issuance Agreement", "type": "category", "uri": "/contracts/tagged/common-stock-issuance-agreement"}, {"name": "Summit Therapeutics Inc.", "type": "company", "uri": "/company/1599298/summit-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "", "id": "ch5niHa3pCJ", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000095012314012620/filename9.htm", "category_name": "Sponsorship Agreement", "company_name": "Summit Corp PLC", "created": "December 4th, 2014", "published": true, "pretty": null, "uri": "/contracts/ch5niHa3pCJ", "title": "DATED 22 November 2013 AGREEMENT FOR THE SPONSORSHIP OF A RESEARCH PROGRAMME", "group_id": "ch5niHa3pCJ", "group_samples": [{"label": "Sponsorship Agreement (Summit Corp PLC)", "uri": "/contracts/ch5niHa3pCJ", "published": true}], "group_size": 1, "tags": [{"name": "Sponsorship Agreement", "type": "category", "uri": "/contracts/tagged/sponsorship-agreement"}, {"name": "Summit Corp PLC", "type": "company", "uri": "/company/1599298/summit-corp-plc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "Summit Therapeutics Inc., a Delaware corporation (the \u201cCompany\u201d), confirms its agreement with J.P. Morgan Securities LLC, as agent and/or principal under any Terms Agreement (as defined in Section 1(a) below) (\u201cyou\u201d or the \u201cAgent\u201d), with respect to the issuance and sale from time to time by the Company, in the manner and subject to the terms and conditions described below in this Distribution Agreement (this \u201cAgreement\u201d), of Common Stock, $0.01 par value per share (the \u201cCommon Stock\u201d), of the Company having an aggregate Gross Sales Price (as defined in Section 2(b) below) of up to $90,000,000 (the \u201cMaximum Amount\u201d) on the terms set forth in Section 1 of this Agreement. Such shares are hereinafter collectively referred to as the \u201cShares\u201d and are described in the Prospectus referred to below.", "id": "dl9zQRPVJgV", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000119312525178022/d56029dex11.htm", "category_name": "Distribution Agreement", "company_name": "Summit Therapeutics Inc.", "created": "August 11th, 2025", "published": true, "pretty": null, "uri": "/contracts/dl9zQRPVJgV", "title": "DISTRIBUTION AGREEMENT", "group_id": "dl9zQRPVJgV", "group_samples": [{"label": "Distribution Agreement (Summit Therapeutics Inc.)", "uri": "/contracts/dl9zQRPVJgV", "published": true}], "group_size": 1, "tags": [{"name": "Distribution Agreement", "type": "category", "uri": "/contracts/tagged/distribution-agreement"}, {"name": "Summit Therapeutics Inc.", "type": "company", "uri": "/company/1599298/summit-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This Rescission Agreement (the \u201cAgreement\u201d) dated as of April 20, 2021 is entered into by and between Summit Therapeutics Inc., a Delaware corporation (the \u201cCompany\u201d) and the Investor.", "id": "eUBbQUwd7Z4", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000119380521000519/ex103to8k12566001_04162021.htm", "category_name": "Rescission Agreement", "company_name": "Summit Therapeutics Inc.", "created": "April 21st, 2021", "published": true, "pretty": null, "uri": "/contracts/eUBbQUwd7Z4", "title": "RESCISSION AGREMENT", "group_id": "eUBbQUwd7Z4", "group_samples": [{"label": "Rescission Agreement (Summit Therapeutics Inc.)", "uri": "/contracts/eUBbQUwd7Z4", "published": true}], "group_size": 1, "tags": [{"name": "Rescission Agreement", "type": "category", "uri": "/contracts/tagged/rescission-agreement"}, {"name": "Summit Therapeutics Inc.", "type": "company", "uri": "/company/1599298/summit-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "", "id": "ehcA4ZmUMUg", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000119312519307884/d824147dex43.htm", "category_name": "Deed of Termination", "company_name": "Summit Therapeutics PLC", "created": "December 6th, 2019", "published": true, "pretty": null, "uri": "/contracts/ehcA4ZmUMUg", "title": "DATE: 6 DECEMBER 2019 DEED OF TERMINATION OF A RELATIONSHIP AGREEMENT DATED 14 DECEMBER 2018 Between SUMMIT THERAPEUTICS PLC ROBERT W. DUGGAN and CAIRN FINANCIAL ADVISERS LLP CMS Cameron McKenna Nabarro Olswang LLP Cannon Place London EC4N 6AF T +44...", "group_id": "ehcA4ZmUMUg", "group_samples": [{"label": "Deed of Termination (Summit Therapeutics PLC)", "uri": "/contracts/ehcA4ZmUMUg", "published": true}], "group_size": 1, "tags": [{"name": "Deed of Termination", "type": "category", "uri": "/contracts/tagged/deed-of-termination"}, {"name": "Summit Therapeutics PLC", "type": "company", "uri": "/company/1599298/summit-therapeutics-plc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "England", "type": "jurisdiction", "uri": "/contracts/tagged/england-gb"}]}, {"intro": "THIS REGISTRATION RIGHTS AGREEMENT (this \u201cAgreement\u201d), dated as of [\u2022], 2026, is entered into by and between Summit Therapeutics Inc., a Delaware corporation (the \u201cCompany\u201d), and AstraZeneca Holdings B.V., a Dutch private limited liability company (together with its permitted assigns, the \u201cInvestor\u201d). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by and among the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the \u201cPurchase Agreement\u201d).", "id": "epOpkFGV2Ec", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000119312526405776/d178892dex102.htm", "category_name": "Registration Rights Agreement", "company_name": "Summit Therapeutics Inc.", "created": "September 29th, 2026", "published": true, "pretty": null, "uri": "/contracts/epOpkFGV2Ec", "title": "FORM OF REGISTRATION RIGHTS AGREEMENT", "group_id": "epOpkFGV2Ec", "group_samples": [{"label": "Registration Rights Agreement (Summit Therapeutics Inc.)", "uri": "/contracts/epOpkFGV2Ec", "published": true}], "group_size": 1, "tags": [{"name": "Registration Rights Agreement", "type": "category", "uri": "/contracts/tagged/registration-rights-agreement"}, {"name": "Summit Therapeutics Inc.", "type": "company", "uri": "/company/1599298/summit-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "", "id": "fOQtcySquqs", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000119312515056561/d822352dex1018.htm", "category_name": "Deed of Indemnity", "company_name": "Summit Therapeutics PLC", "created": "February 20th, 2015", "published": true, "pretty": null, "uri": "/contracts/fOQtcySquqs", "title": "DEED OF INDEMNITY", "group_id": "fOQtcySquqs", "group_samples": [{"label": "Deed of Indemnity (Summit Therapeutics PLC)", "uri": "/contracts/fOQtcySquqs", "published": true}], "group_size": 1, "tags": [{"name": "Deed of Indemnity", "type": "category", "uri": "/contracts/tagged/deed-of-indemnity"}, {"name": "Summit Therapeutics PLC", "type": "company", "uri": "/company/1599298/summit-therapeutics-plc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "England", "type": "jurisdiction", "uri": "/contracts/tagged/england-gb"}]}, {"intro": "", "id": "g8cjYE98X99", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000159929826000068/amendmentno3edgarversion.htm", "category_name": "Collaboration and License Agreement", "company_name": "Summit Therapeutics Inc.", "created": "July 23rd, 2026", "published": true, "pretty": null, "uri": "/contracts/g8cjYE98X99", "title": "Contract", "group_id": "g8cjYE98X99", "group_samples": [{"label": "Collaboration and License Agreement (Summit Therapeutics Inc.)", "uri": "/contracts/g8cjYE98X99", "published": true}], "group_size": 1, "tags": [{"name": "Collaboration and License Agreement", "type": "category", "uri": "/contracts/tagged/collaboration-and-license-agreement"}, {"name": "Summit Therapeutics Inc.", "type": "company", "uri": "/company/1599298/summit-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Consulting Agreement (the \u201cAgreement\u201d) dated December 6, 2019 is entered into by and between Summit Therapeutics plc, a public limited company incorporated in England and Wales with the Registrar of Companies of England and Wales (the \u201cCompany\u201d), having a principal place of business at 136a Eastern Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4SB, United Kingdom, and Maky Zanganeh & Associates, Inc., a California corporation (\u201cConsultant\u201d), having a business address at 2882 Sand Hill Rd., Suite 106, Menlo Park, California 94025, United States of America. The Company and Consultant are each a \u201cParty\u201d hereunder and collectively \u201cthe Parties.\u201d The Agreement will be effective upon the date of Admission (as such term is defined in the Company\u2019s circular to shareholders dated on or around the date of this Agreement in connection with a proposed equity investment in the Company by Robert Duggan) (the \u201cEffective Date\u201d).", "id": "h5sHERp2jjS", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000119312519307884/d824147dex44.htm", "category_name": "Consulting Agreement", "company_name": "Summit Therapeutics PLC", "created": "December 6th, 2019", "published": true, "pretty": null, "uri": "/contracts/h5sHERp2jjS", "title": "CONSULTING AGREEMENT", "group_id": "h5sHERp2jjS", "group_samples": [{"label": "Consulting Agreement (Summit Therapeutics PLC)", "uri": "/contracts/h5sHERp2jjS", "published": true}], "group_size": 1, "tags": [{"name": "Consulting Agreement", "type": "category", "uri": "/contracts/tagged/consulting-agreement"}, {"name": "Summit Therapeutics PLC", "type": "company", "uri": "/company/1599298/summit-therapeutics-plc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "California", "type": "jurisdiction", "uri": "/contracts/tagged/california-us"}]}, {"intro": "", "id": "h7m3hjOyFMn", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000159929824000117/amd3tosublease-for10xqwi.htm", "category_name": "Sublease", "company_name": "Summit Therapeutics Inc.", "created": "August 6th, 2024", "published": true, "pretty": null, "uri": "/contracts/h7m3hjOyFMn", "title": "Certain confidential information obtained in this document, marked by [**], has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) the type of information that the registrant treats as private...", "group_id": "h7m3hjOyFMn", "group_samples": [{"label": "Sublease (Summit Therapeutics Inc.)", "uri": "/contracts/h7m3hjOyFMn", "published": true}], "group_size": 1, "tags": [{"name": "Sublease", "type": "category", "uri": "/contracts/tagged/sublease"}, {"name": "Summit Therapeutics Inc.", "type": "company", "uri": "/company/1599298/summit-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "THIS SUBLEASE, made and entered into as of the 1st day of March, 2021, by and between MAKY ZANGANEH & ASSOCIATES INC, a California corporation having an office and place of business at 2882 San Hill Road, Suite 106, Menlo Park, CA 94025, hereinafter called \"Sublandlord\", and SUMMIT THERAPUETICS SUB INC. a Delaware corporation, having an office and principal place of business at One Broadway 14th Floor Cambridge, MA 02142.", "id": "hQkpUhP3xeJ", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000159929821000011/sum-ex1036_20201231x10k.htm", "category_name": "Sublease", "company_name": "Summit Therapeutics Inc.", "created": "March 31st, 2021", "published": true, "pretty": null, "uri": "/contracts/hQkpUhP3xeJ", "title": "SUBLEASE", "group_id": "hQkpUhP3xeJ", "group_samples": [{"label": "Sublease (Summit Therapeutics Inc.)", "uri": "/contracts/hQkpUhP3xeJ", "published": true}], "group_size": 1, "tags": [{"name": "Sublease", "type": "category", "uri": "/contracts/tagged/sublease"}, {"name": "Summit Therapeutics Inc.", "type": "company", "uri": "/company/1599298/summit-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "", "id": "iFLmvpSC7dE", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000159929823000012/exhibit101amendment1toak.htm", "category_name": "Collaboration and License Agreement", "company_name": "Summit Therapeutics Inc.", "created": "January 20th, 2023", "published": true, "pretty": null, "uri": "/contracts/iFLmvpSC7dE", "title": "AMENDMENT No. 1 to Collaboration and License Agreement between Akeso, Inc. and Summit Therapeutics Sub, Inc. This Amendment No. 1 (\u201cAmendment No. 1\u201d or \u201cAmendment\u201d) is entered into as of January 16, 2023 (\u201cAmendment No. 1 Effective Date\u201d) by and...", "group_id": "iFLmvpSC7dE", "group_samples": [{"label": "Collaboration and License Agreement (Summit Therapeutics Inc.)", "uri": "/contracts/iFLmvpSC7dE", "published": true}], "group_size": 1, "tags": [{"name": "Collaboration and License Agreement", "type": "category", "uri": "/contracts/tagged/collaboration-and-license-agreement"}, {"name": "Summit Therapeutics Inc.", "type": "company", "uri": "/company/1599298/summit-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This MDA Venture Philanthropy Corporate Grant Contract (\u201cContract\u201d) is entered into as of December 15, 2011 (the \u201cEffective Date\u201d), between Muscular Dystrophy Association, Inc., a New York not-for-profit corporation (\u201cMDA\u201d) and Summit Corporation plc, a company incorporated in England and listed on the Alternative Investment Market of the London Stock Exchange having its registered office at 91 Milton Park, Abingdon, Oxfordshire, OX14 4RY, England (\u201cGRANTEE\u201d), to document the terms upon which MDA will provide funding for the Project (as defined below) and certain related matters. MDA and GRANTEE are sometimes referred to herein individually as a \u201cParty\u201d and collectively as the \u201cParties.\u201d", "id": "j4eL8snlCrU", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000119312515028037/d822352dex102.htm", "category_name": "Grant Contract", "company_name": "Summit Corp PLC", "created": "January 30th, 2015", "published": true, "pretty": null, "uri": "/contracts/j4eL8snlCrU", "title": "MDA Venture Philanthropy Grant Contract Between Muscular Dystrophy Association, Inc. and Summit Corporation plc (for the development of DMD and/or BMD therapeutics)", "group_id": "j4eL8snlCrU", "group_samples": [{"label": "Grant Contract (Summit Corp PLC)", "uri": "/contracts/j4eL8snlCrU", "published": true}], "group_size": 1, "tags": [{"name": "Grant Contract", "type": "category", "uri": "/contracts/tagged/grant-contract"}, {"name": "Summit Corp PLC", "type": "company", "uri": "/company/1599298/summit-corp-plc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "", "id": "jSh3w2gKhMt", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000159929823000034/amd2tosublease.htm", "category_name": "Sublease", "company_name": "Summit Therapeutics Inc.", "created": "March 9th, 2023", "published": true, "pretty": null, "uri": "/contracts/jSh3w2gKhMt", "title": "SECOND AMENDMENT TO SUBLEASE ThisSECONDAMENDMENTTOSUBLEASE(this\"Second Amendment\") has an Effective Date of the 1st day of August, 2022, by and between MAKY ZANGANEH & ASSIOCIATES INC., a California corporation (hereinafter called \"Sublandlord\"), and...", "group_id": "jSh3w2gKhMt", "group_samples": [{"label": "Sublease (Summit Therapeutics Inc.)", "uri": "/contracts/jSh3w2gKhMt", "published": true}], "group_size": 1, "tags": [{"name": "Sublease", "type": "category", "uri": "/contracts/tagged/sublease"}, {"name": "Summit Therapeutics Inc.", "type": "company", "uri": "/company/1599298/summit-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "", "id": "kFCS2KYaWKv", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000119312518350442/d639714dex102.htm", "category_name": "Relationship Agreement", "company_name": "Summit Therapeutics PLC", "created": "December 17th, 2018", "published": true, "pretty": null, "uri": "/contracts/kFCS2KYaWKv", "title": "DATE: DECEMBER 14, 2018 RELATIONSHIP AGREEMENT RELATING TO SUMMIT THERAPEUTICS PLC Between SUMMIT THERAPEUTICS PLC and ROBERT W. DUGGAN and CAIRN FINANCIAL ADVISERS LLP CMS Cameron McKenna Nabarro Olswang LLP Cannon Place London EC4N 6AF T +44 20 7367...", "group_id": "kFCS2KYaWKv", "group_samples": [{"label": "Relationship Agreement (Summit Therapeutics PLC)", "uri": "/contracts/kFCS2KYaWKv", "published": true}], "group_size": 1, "tags": [{"name": "Relationship Agreement", "type": "category", "uri": "/contracts/tagged/relationship-agreement"}, {"name": "Summit Therapeutics PLC", "type": "company", "uri": "/company/1599298/summit-therapeutics-plc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "England and Wales", "type": "jurisdiction", "uri": "/contracts/tagged/england-and-wales-gb"}]}, {"intro": "This SECURITIES PURCHASE AGREEMENT (this \u201cAgreement\u201d) is made and entered into as of December 6, 2019 by and among Summit Therapeutics plc, a public limited company incorporated in England and Wales with the Registrar of Companies of England and Wales, with its principal place of business at 136a Eastern Avenue, Milton Park, Abingdon, Oxfordshire OX14 4SB, United Kingdom (the \u201cCompany\u201d), and the investor named on Exhibit A hereto (the \u201cInvestor\u201d).", "id": "kGUbuRPdXHQ", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000119312519307884/d824147dex41.htm", "category_name": "Securities Purchase Agreement", "company_name": "Summit Therapeutics PLC", "created": "December 6th, 2019", "published": true, "pretty": null, "uri": "/contracts/kGUbuRPdXHQ", "title": "SECURITIES PURCHASE AGREEMENT", "group_id": "kGUbuRPdXHQ", "group_samples": [{"label": "Securities Purchase Agreement (Summit Therapeutics PLC)", "uri": "/contracts/kGUbuRPdXHQ", "published": true}], "group_size": 1, "tags": [{"name": "Securities Purchase Agreement", "type": "category", "uri": "/contracts/tagged/securities-purchase-agreement"}, {"name": "Summit Therapeutics PLC", "type": "company", "uri": "/company/1599298/summit-therapeutics-plc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This Contract (\u201cContract\u201d) is entered into as of 15th December, 2011, between Duchenne Partners Fund, Inc., a Delaware limited liability company (\u201cDPF\u201d), and Summit Corporation plc, a company incorporated in England and listed on the Alternative Investment Market of the London Stock Exchange having its registered office at 91 Milton Park, Abingdon, Oxfordshire, OX14 4RY, England (\u201cGRANTEE\u201d), to document the terms upon which DPF will provide funding for the Project (as defined below) and certain related matters. DPF and GRANTEE are sometimes referred to herein individually as a \u201cParty\u201d and collectively as the \u201cParties.\u201d", "id": "kITCLgXlaHG", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000119312515028037/d822352dex101.htm", "category_name": "Grant Agreement", "company_name": "Summit Corp PLC", "created": "January 30th, 2015", "published": true, "pretty": null, "uri": "/contracts/kITCLgXlaHG", "title": "Grant Agreement Between Duchenne Partners Fund, and Summit Corporation plc (for the development of DMD and or BMD therapeutics)", "group_id": "kITCLgXlaHG", "group_samples": [{"label": "Grant Agreement (Summit Corp PLC)", "uri": "/contracts/kITCLgXlaHG", "published": true}], "group_size": 1, "tags": [{"name": "Grant Agreement", "type": "category", "uri": "/contracts/tagged/grant-agreement"}, {"name": "Summit Corp PLC", "type": "company", "uri": "/company/1599298/summit-corp-plc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "", "id": "kiYrPTfqjwy", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000159929825000126/paloaltosub-sublease.htm", "category_name": "Sub-Sublease Agreement", "company_name": "Summit Therapeutics Inc.", "created": "August 11th, 2025", "published": true, "pretty": null, "uri": "/contracts/kiYrPTfqjwy", "title": "Certain confidential information contained in this document, marked by [**], has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) the type of information that the registrant treats as private...", "group_id": "kiYrPTfqjwy", "group_samples": [{"label": "Sub Sublease Agreement (Summit Therapeutics Inc.)", "uri": "/contracts/kiYrPTfqjwy", "published": true}], "group_size": 1, "tags": [{"name": "Sub-Sublease Agreement", "type": "category", "uri": "/contracts/tagged/sub-sublease-agreement"}, {"name": "Summit Therapeutics Inc.", "type": "company", "uri": "/company/1599298/summit-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "THIS EMPLOYMENT AGREEMENT (the \u201cAgreement\u201d) is made and entered into as of October 13, 2023, by and between Summit Therapeutics, Inc., a Delaware corporation (together with its successors and assigns permitted hereunder, the \u201cCompany\u201d), and Manmeet S. Soni (the", "id": "kmyqLrxMhmY", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000159929823000098/sum-ex101xmsoniemploymenta.htm", "category_name": "Employment Agreement", "company_name": "Summit Therapeutics Inc.", "created": "November 7th, 2023", "published": true, "pretty": null, "uri": "/contracts/kmyqLrxMhmY", "title": "EMPLOYMENT AGREEMENT", "group_id": "kmyqLrxMhmY", "group_samples": [{"label": "Employment Agreement (Summit Therapeutics Inc.)", "uri": "/contracts/kmyqLrxMhmY", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Summit Therapeutics Inc.", "type": "company", "uri": "/company/1599298/summit-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "THIS LICENSE AND COMMERCIALIZATION AGREEMENT (this \u201cAgreement\u201d), effective as of December 18, 2017 (the \u201cEffective Date\u201d), is entered into by and between Summit (Oxford) Ltd, a limited company incorporated in England (with registered number 04636431) whose registered office is at 136a Eastern Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4SB, United Kingdom (\u201cSummit\u201d) and Eurofarma Laborat\u00f3rios S.A., a company incorporated in Brazil (with registered number 61.190.096/0001-92), whose principal place of business is at Avenue Vereador Jos\u00e9 Diniz, 3465, Campo Belo, S\u00e3o Paulo/SP, Brazil (\u201cEurofarma\u201d).", "id": "lR70LRtSKVD", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000162828018004229/sum-ex427_20180131x20f.htm", "category_name": "License and Commercialization Agreement", "company_name": "Summit Therapeutics PLC", "created": "April 13th, 2018", "published": true, "pretty": null, "uri": "/contracts/lR70LRtSKVD", "title": "LICENSE AND COMMERCIALIZATION AGREEMENT by and between SUMMIT (OXFORD) LTD and EUROFARMA LABORAT\u00d3RIOS S.A.", "group_id": "lR70LRtSKVD", "group_samples": [{"label": "License and Commercialization Agreement (Summit Therapeutics PLC)", "uri": "/contracts/lR70LRtSKVD", "published": true}], "group_size": 1, "tags": [{"name": "License and Commercialization Agreement", "type": "category", "uri": "/contracts/tagged/license-and-commercialization-agreement"}, {"name": "Summit Therapeutics PLC", "type": "company", "uri": "/company/1599298/summit-therapeutics-plc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This SECURITIES PURCHASE AGREEMENT (this \u201cAgreement\u201d) is dated as of October 21, 2025, by and among Summit Therapeutics Inc., a Delaware corporation (the \u201cCompany\u201d), and each of the entities listed on Exhibit A attached to this Agreement (each, an \u201cInvestor\u201d and together, the \u201cInvestors\u201d).", "id": "lvgWnk7fHRo", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000119312525245790/d274712dex101.htm", "category_name": "Securities Purchase Agreement", "company_name": "Summit Therapeutics Inc.", "created": "October 22nd, 2025", "published": true, "pretty": null, "uri": "/contracts/lvgWnk7fHRo", "title": "SECURITIES PURCHASE AGREEMENT", "group_id": "lvgWnk7fHRo", "group_samples": [{"label": "Securities Purchase Agreement (Summit Therapeutics Inc.)", "uri": "/contracts/lvgWnk7fHRo", "published": true}], "group_size": 1, "tags": [{"name": "Securities Purchase Agreement", "type": "category", "uri": "/contracts/tagged/securities-purchase-agreement"}, {"name": "Summit Therapeutics Inc.", "type": "company", "uri": "/company/1599298/summit-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "", "id": "vC7psF4sRt", "source_url": "https://www.sec.gov/Archives/edgar/data/1599298/000159929824000117/summit-akesoxamendment2t.htm", "category_name": "Collaboration and License Agreement", "company_name": "Summit Therapeutics Inc.", "created": "August 6th, 2024", "published": true, "pretty": null, "uri": "/contracts/vC7psF4sRt", "title": "Certain confidential information obtained in this document, marked by [**], has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) the type of information that the registrant treats as private...", "group_id": "vC7psF4sRt", "group_samples": [{"label": "Collaboration and License Agreement (Summit Therapeutics Inc.)", "uri": "/contracts/vC7psF4sRt", "published": true}], "group_size": 1, "tags": [{"name": "Collaboration and License Agreement", "type": "category", "uri": "/contracts/tagged/collaboration-and-license-agreement"}, {"name": "Summit Therapeutics Inc.", "type": "company", "uri": "/company/1599298/summit-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}], "next_curs": "", "cursor": "CjEKEAoKZ3JvdXBfc2l6ZRICCAEKGQoIZ3JvdXBfaWQSDRoLNkx6U0taODdLTlYYACAB"}}